leaders in innovation
Levact 25mg and 100mg powder for concentrate for solution for infusion is indicated for: First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate. Indolent non-Hodgkin's lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.
DepoCyte 50 mg suspension for injection is indicated for intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.

Mundipharma Pharmaceuticals associated companies, Mundipharma Research Limited in Cambridge and Mundipharma Research GmbH in Germany, are young,...


What is asthma?
Asthma is a common medical condition that affects the lungs.
More specifically, asthma causes...


We are actively involved in the following therapeutic areas: Analgesia, Oncology, and Respiratory.


Analgesia is our...


Mundipharma Pharmaceuticals Limited is an Irish company and is part of a network of independent associated companies across Europe. This...

keep me informed

Keep me Informed

Receive Emails about special offers, promotions, products and news.

Mundipharma newsletter

events calendar
Events Calendar
Medical Information &

Medical Information & Adverse Events

Contact Medical Information on:

01 2063800
1800 991 830 (outside office hours)

For Adverse Events email: